| Dr Zachary Laucis, DO | |
|
621 Memorial Dr, Ste 502, South Bend, IN 46601-1075 | |
| (574) 647-5875 | |
| Not Available |
| Full Name | Dr Zachary Laucis |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 10 Years |
| Location | 621 Memorial Dr, South Bend, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497168314 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 5151012927 (Michigan) | Secondary |
| 208600000X | Surgery | 036150381 (Illinois) | Secondary |
| 208600000X | Surgery | 02006533A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital Of South Bend | South bend, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Beacon Medical Group Inc | 1254243306 | 452 |
News Archive
San Diego-based Concerro, Inc., the market leader in enterprise-wide hospital shift and disaster workforce management software, has enhanced its CommandAware® hospital incident management system by adding a new location-based intelligence tool to help clients identify and interact with regional data in a more efficient way.
For a disheartening example of how intense lobbying and financial contributions can distort the legislative process in Washington, consider what happened to the "fiscal cliff" bill approved three weeks ago by Congress.
Conceptus Inc., developer of the Essure(R) procedure, the first and proven non-surgical permanent birth control method, announced today that the third generation (ESS305) of the Essure procedure has received FDA-approval for an improved bilateral placement rate of 96.9%. Improvement in the hysteroscopic time of 9 minutes is an additional benefit.
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Tumor repressor genes, which inhibit tumor formation, can be "turned off" due to undesirable molecular changes affecting the chromosomes on which the genes reside. Understanding and being able to control these alterations could lead to new approaches for activating or inactivating genes linked to cancer.
› Verified 3 days ago
| Entity Name | Beacon Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033161617 PECOS PAC ID: 1254243306 Enrollment ID: O20031105000657 |
News Archive
San Diego-based Concerro, Inc., the market leader in enterprise-wide hospital shift and disaster workforce management software, has enhanced its CommandAware® hospital incident management system by adding a new location-based intelligence tool to help clients identify and interact with regional data in a more efficient way.
For a disheartening example of how intense lobbying and financial contributions can distort the legislative process in Washington, consider what happened to the "fiscal cliff" bill approved three weeks ago by Congress.
Conceptus Inc., developer of the Essure(R) procedure, the first and proven non-surgical permanent birth control method, announced today that the third generation (ESS305) of the Essure procedure has received FDA-approval for an improved bilateral placement rate of 96.9%. Improvement in the hysteroscopic time of 9 minutes is an additional benefit.
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Tumor repressor genes, which inhibit tumor formation, can be "turned off" due to undesirable molecular changes affecting the chromosomes on which the genes reside. Understanding and being able to control these alterations could lead to new approaches for activating or inactivating genes linked to cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Zachary Laucis, DO 3245 Health Drive, Suite 100, Granger, IN 46530-3245 Ph: (574) 647-1840 | Dr Zachary Laucis, DO 621 Memorial Dr, Ste 502, South Bend, IN 46601-1075 Ph: (574) 647-5875 |
News Archive
San Diego-based Concerro, Inc., the market leader in enterprise-wide hospital shift and disaster workforce management software, has enhanced its CommandAware® hospital incident management system by adding a new location-based intelligence tool to help clients identify and interact with regional data in a more efficient way.
For a disheartening example of how intense lobbying and financial contributions can distort the legislative process in Washington, consider what happened to the "fiscal cliff" bill approved three weeks ago by Congress.
Conceptus Inc., developer of the Essure(R) procedure, the first and proven non-surgical permanent birth control method, announced today that the third generation (ESS305) of the Essure procedure has received FDA-approval for an improved bilateral placement rate of 96.9%. Improvement in the hysteroscopic time of 9 minutes is an additional benefit.
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Tumor repressor genes, which inhibit tumor formation, can be "turned off" due to undesirable molecular changes affecting the chromosomes on which the genes reside. Understanding and being able to control these alterations could lead to new approaches for activating or inactivating genes linked to cancer.
› Verified 3 days ago
Marie E Unruh, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Navarre Pl Ste 5500, South Bend, IN 46601 Phone: 574-647-5200 Fax: 574-647-5210 | |
Dr. Robert G. Credi, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 621 Memorial Dr Ste 502, South Bend, IN 46601 Phone: 574-647-5875 Fax: 574-647-5878 | |
Scott G Thomas, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 621 Memorial Dr, Suite 502, South Bend, IN 46601 Phone: 574-647-5875 Fax: 574-647-5878 | |
Michael C Rotkis, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 621 Memorial Dr, South Bend, IN 46601 Phone: 574-236-1888 Fax: 574-236-1887 | |
William Anderson, MD Surgery Medicare: Medicare Enrolled Practice Location: 621 Memorial Dr, Ste 502, South Bend, IN 46601 Phone: 574-647-5875 Fax: 515-643-5802 | |
George B Friend, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 621 Memorial Dr, South Bend, IN 46601 Phone: 574-236-1888 Fax: 574-236-1888 | |
Daniel P. Srikureja, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 621 Memorial Dr Ste 502, South Bend, IN 46601 Phone: 574-647-5875 Fax: 574-647-5878 |